AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.

Trial Details

NCT ID
NCT06340737
Phase
PHASE1
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Hairy Cell Leukemia Leukemia
Interventions
  • CD22CART Infusion
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Disease: Must have histologically confirmed disease as defined by WHO 2016\[117\] of one of the following:
  • Follicular Lymphoma, grade 1-3a
  • Relapsed or refractory disease after at least 2 lines of systemic therapy. Prior therapy must have included an anti-CD20 monoclonal antibody combin…
  • Relapsed or progressive disease within 24 months of initiation of the initial course of chemotherapy (also known as progression of disease within 2…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hairy Cell Leukemia Leukemia Trials on Trialify →